development of an acceptable, long-range, comprehensive action plan, the Department has asked the Keystone Center to serve as a facilitator to provide the organizational and logistical services and expertise for the development of this plan. The Keystone Center is a private, nonprofit public policy, science, and education organization that has broad experience in bringing together the diverse views of industry, consumer, and health professional groups. Additionally, the Department has asked the Keystone Center to form, in consultation with the Department, a steering committee that will solicit and coordinate input from all interested parties and oversee the development of the plan.

The Department requests that all parties who represent national organizations and wish to participate on the steering committee, submit the following information to the Keystone Center (address above): (1) Name of individual and organization, (2) specification or certification that the organization is of national standing, (3) type of group represented (e.g., health care professionals, consumers, pharmaceutical manufacturers), (4) size of membership, (5) relevance of the organization to the plan goals or organizational interest in participation in development of the plan, and (6) address, e-mail, telephone number, and facsimile number of individual and alternate contact. Due to the shore timeframes specified in the Appropriations Act, this submission should be received [by] no later than 5 p.m. (EDT), September 3, 1996.

The Keystone Center, in consultation with the Department, will select organization representatives from the submissions to become members of the steering committee. The committee will then solicit input from *all* interested parties and may hold a series of meetings to allow the parties to discuss and develop the plan. The first meeting of the steering committee will be hosted by the Department at a time and place to be announced. Invitations will be issued to the selected representatives. At this meeting, representatives from the Department and from the Keystone Center will discuss the development of an action plan and be available to answer questions.

Dated: August 23, 1996.

Donna E. Shalala,

Secretary of Health and Human Services.

[FR Doc. 96–21942 Filed 8–23–96; 12:08 am]

BILLING CODE 4110–60–M

Centers for Disease Control and Prevention

Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites: Idaho National Engineering Laboratory Health Effects Subcommittee

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites: Idaho National Engineering Laboratory (INEL) Health Effects Subcommittee.

Times and Dates: 8 a.m.–5 p.m., September 10, 1996, 7 p.m.–9 p.m., September 10, 1996, 8 a.m.–12:15 p.m., September 11, 1996.

Place: Best Western Canyon Springs Inn, 1357 Blue Lakes Boulevard North, Twin Falls, Idaho 83301, telephone 208/734–5000.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

Purpose: The Subcommittee is charged with providing advice and recommendations to the Director, CDC, and the Administrator, ATSDR, regarding community, American Indian Tribes, and labor concerns pertaining to CDC's and ATSDR's public health activities and research at respective DOE sites. Activities shall focus on providing a forum for community, American Indian Tribal, and labor interaction and serve as a vehicle for community concern to be expressed as advice and recommendations to CDC and ATSDR.

Matters to be Discussed: Agenda items include presentations from the National Center for Environmental Health (NCEH), the National Institute for Occupational Safety and Health, and ATSDR, on the progress of current studies. On September 10, at 7 p.m., the meeting will continue in order to allow more time for public input and comment.

Agenda items are subject to change as priorities dictate.

Contact Persons For More Information: Arthur J. Robinson or Nadine Dickerson, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, M/S F–35, Atlanta, Georgia 30341–3724, telephone 770/488–7040, FAX 770/488–7044.

Dated: August 21, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–21780 Filed 8–23–96; 8:45 am]

BILLING CODE 4163–18–M

Administration for Children and Families

President's Committee on Mental Retardation; Notice of Meeting

Agency Holding the Meeting: President's Committee on Mental Retardation.

Time and Date: Full Committee Meeting, September 26, 1996, 2:00 p.m.–8:00 p.m.

Place: Crystal City Courtyard by Marriott, 2899 Jefferson Davis Highway, Arlington, Virginia 22202.

Status: Meetings are open to the public. An interpreter for the deaf will be available upon advance request. All locations are barrier free.

To Be Considered: The Committee plans to discuss critical issues concerning Federal Policy, Federal Research and Demonstration, State Policy Collaboration, Minority and Cultural Diversity and Mission and Public Awareness.

The PCMR acts in an advisory capacity to the President and the Secretary of the U.S. Department of Health and Human Services on a broad range of topics relating to programs and services for persons with mental retardation. The Committee, by Executive Order, is responsible for evaluating the adequacy of current practices in programs for persons with mental retardation, and for reviewing legislative proposals that impact the quality of life that is experienced by citizens with mental retardation and their families.

Contact Person for More Information: Gary H. Blumenthal, 352–G Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201–0001, (202) 619–0634.

Dated: August 19, 1996.

Gary H. Blumenthal,

Executive Director, PCMR.

[FR Doc. 96–21648 Filed 8–23–96; 8:45 am]

BILLING CODE 4184–01–M

Food and Drug Administration

Blood Donor Incentive Programs for Volunteer (Non-remunerated) Donors; Notice of Public Workshop

AGENCY: Food and Drug Administration, HHS

ACTION: Notice of public workshop.

SUMMARY: The Food and Drug Administration (FDA) and the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health are announcing a public workshop to discuss the use of donor

incentive programs to recruit donors of blood and blood products. The purpose of the workshop, sponsored by FDA and NHLBI, is to gather information regarding the use of blood donor incentive programs to motivate persons to become donors and the suitability of donors recruited by the incentives. The information gathered during the workshop will be useful to FDA and NHLBI in determining whether donor incentive programs could affect the safety and/or availability of blood.

DATES: The public workshop will be held on Wednesday, September 25, 1996, from 8 a.m. to 4:30 p.m. Registration is requested by September 18, 1996, and is recommended because seating is limited to 350. Registration at the site will be done on a space-available basis on the day of the workshop beginning at 7:30 a.m.

ADDRESSES: The public workshop will be held at the Holiday Inn Bethesda, 8120 Wisconsin Ave., Bethesda, MD.

FOR FURTHER INFORMATION CONTACT: Joseph Wilczek, Office of Blood Research and Review (HFM–350), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–3514.

Those persons interested in attending this workshop should FAX their registration to 301–827–2843, including name, title, firm name, address, and telephone number. There is no registration fee for this workshop, but advance registration is requested. Interested parties are encouraged to register early because space is limited.

SUPPLEMENTARY INFORMATION: FDA is charged with overseeing the safety of the nation's blood supply. In 1978, FDA published labeling requirements for blood and blood products that were intended to reduce the risk of transfusion-associated hepatitis by establishing categories of paid and volunteer donors. Paid donor labeling did not include donor incentives such as lotteries, time off from work, novelties, and other similar incentives. Such incentives have been used with increasing frequency since the labeling requirements were published. Recent circumstances have raised concerns within the agency and prompted FDA to schedule this workshop. One concern is that some currently used incentives may lead to recruitment of donors whose blood is unsuitable for blood and plasma donation. FDA is concerned that some unsuitable donors, intent on receiving a particular incentive, may not be fully candid and truthful during predonation screening. In addition, there may be certain recruiting situations where unsuitable donors who are members of a recruited group may feel compelled or coerced to participate (donate) in support of the group initiative. Another general concern is the possibility that an increased level of competition for suitable donors may affect the safety of the blood supply. A goal of the workshop is to gather data and information on the positive and negative effects of donor incentive programs. Interested members of the public are invited to attend the workshop and to present their experiences with blood and plasma donor incentive programs. Discussion sessions allowing for questions and answers are planned for the following topics: (1) Current Definitions: Paid vs. Volunteer Blood Donors; (2) Paid Donations and Recruitment Practices; (3) Donor Motivational Factors-Volunteer/Autologous/Designated/Non-volunteer; (4) Public Health Risk/Benefits of Using Donor Incentives; and (5) Panel Discussions and Questions. Information presented at this workshop will assist FDA in determining whether further action may be appropriate.

Dated: August 20, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96–21729 Filed 8–21–96; 3:33 pm]

BILLING CODE 4160–01–F

[Docket No. 96F–0292]

Cytec Industries, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Cytec Industries, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of polyethyleneglycol alkyl (C_{10}–C_{12}) ether sulfosuccinate, disodium salt as a component of adhesives and as an emulsifier and/or surface-active agent in the manufacture of articles or components of articles intended for use in contact with food.

DATES: Written comments on the petitioner's environmental assessment by September 25, 1996.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS–216),Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3081.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 6B4518) has been filed by Cytec Industries, Inc., c/o Keller and Heckman, 1001 G St. NW., suite 500 West, Washington, DC 20001. The petition proposes to amend the food additive regulations to provide for the safe use of polyethyleneglycol alkyl (C_{10}–C_{12}) ether sulfosuccinate, disodium salt as a component of adhesives and as an emulsifier and/or surface-active agent in the manufacture of articles or components of articles intended for use in contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before September 25, 1996, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: August 8, 1996.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 96–21652 Filed 8–23–96; 8:45 am]

BILLING CODE 4160–01–F